Immune characterization of breast cancer metastases: prognostic implications
Maria Vittoria Dieci(Istituto Oncologico Veneto), Valentina Guarneri(Istituto Oncologico Veneto), Grazia Maria Vernaci(University of Padua), Serena Bonaguro(University of Padua), Giulia Tasca(University of Padua), Vassilena Tsvetkova(University of Padua), PierFranco Conte(University of Padua), Claudia Omarini(University of Modena and Reggio Emilia), Rocco Cappellesso(University of Padua), Guido Ficarra(University of Modena and Reggio Emilia), Tommaso Giarratano(Istituto Oncologico Veneto), Giovanni Faggioni(Istituto Oncologico Veneto), Enrico Orvieto(AULSS 2 Marca Trevigiana), Carlo Alberto Giorgi(Istituto Oncologico Veneto), Gaia Griguolo(University of North Carolina at Chapel Hill), Federica Miglietta(University of Padua), Federico Piacentini(Azienda Unita' Sanitaria Locale Di Modena), Camillo Aliberti(Università Cattolica del Sacro Cuore)
Cited by 89
Related Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
|JAMA Oncology|2019|983
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830